Meeting
2015 Breast Cancer Symposium
Association of PIK3CA mutation with response (ExRx) to cetuximab (C) in metastatic (met) triple-negative breast cancer (TNBC).
Authors
Joyce O'Shaughnessy
Baylor Sammons Cancer Ctr US Onc, Dallas, TX
Joyce O'Shaughnessy , Corinne Ramos , Phil Stephens , Nicholas N Hoke , Norma Alonzo Palma , Maren K. Levin , Marina Horiates , Christine E. Horak , Kai Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Systemic Therapy, Survivorship, and Health Policy
Track
Systemic Therapy,Local/Regional Therapy,Survivorship and Health Policy
Sub Track
Triple-Negative
Citation
J Clin Oncol 33, 2015 (suppl 28S; abstr 151)
DOI
10.1200/jco.2015.33.28_suppl.151
Abstract #
151
Poster Bd #
J4
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Next-generation sequencing (NGS) in relapsed/refractory triple-negative breast cancer (TNBC) in Israel.
First Author: Noa Ben-Baruch
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis.
First Author: Steven Brad Maron
Poster
2018 Genitourinary Cancers Symposium
Molecular profiles of small cell bladder and prostate cancer and comparisons with small cell lung cancer.
First Author: Nancy Ann Dawson
Poster
2017 Genitourinary Cancers Symposium
Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.
First Author: Werner J. Struss